Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000421712 | SCV000517494 | benign | not specified | 2015-12-10 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Genome- |
RCV001549069 | SCV001769148 | benign | Nephrotic syndrome, type 9 | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000676540 | SCV002405429 | benign | not provided | 2025-02-03 | criteria provided, single submitter | clinical testing | |
Unidad de Genómica Garrahan, |
RCV000421712 | SCV005087496 | benign | not specified | 2024-07-15 | criteria provided, single submitter | clinical testing | This variant is classified as Benign based on local population frequency. This variant was detected in 65% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 60. Only high quality variants are reported. |
Breakthrough Genomics, |
RCV000676540 | SCV005307313 | benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000676540 | SCV000802325 | benign | not provided | 2016-02-19 | no assertion criteria provided | clinical testing |